Saint-Herblain (France), March 3, 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA) a specialty vaccine company, today announced that its senior management will participate at upcoming investor conferences in the United States and Europe. CEO Thomas Lingelbach and CFO Peter Bühler will present at the TD Cowen 45th Annual Health Care Conference, taking place March 3 – 5, 2025, in Boston, MA. Mr. Lingelbach and Mr. Peter Bühler will also meet with institutional investors during the Van Lanschot Kempen Life Sciences Conference, held April 2 – 3, 2025, in Amsterdam, The Netherlands.
Management will discuss Valneva’s pipeline of potential first-in-class vaccine candidates, including its lead Lyme disease vaccine, VLA15, and its Shigella and Zika programs alongside the Company’s portfolio of marketed vaccines, which are expected to generate €170-180 million in revenue in 2025.
The TD Cowen presentation will be webcast live and available as a replay in the “investor” section of the Valneva website at www.valneva.com.
TD Cowen 45th Annual Health Care Conference
Date/Time: March 4, 1:10pm ET
Format: Presentation and investor meetings
Location: Boston, Massachusetts
Webcast Link: https://wsw.com/webcast/cowen177/vla/1855281
Van Lanschot Kempen Life Sciences Conference
Date/Time: April 3
Format: Investor meetings
Location: Amsterdam, The Netherlands
Attending institutional investors who would like to meet with Valneva management are asked to submit a request to their representative at the respective bank.
About …
